Egetis Therapeutics AB (publ) (EGTX) — Working Capital to Net Assets Ratio
Egetis Therapeutics AB (publ) (EGTX) has a Working Capital to Net Assets ratio of 5.5% as of June 2025. Working capital of Skr19.70 Million (current assets of Skr246.40 Million minus current liabilities of Skr226.70 Million) is measured against net assets of Skr355.10 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See EGTX net asset quality score to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Egetis Therapeutics AB (publ) Working Capital to Net Assets (2008–2024)
This chart shows how Egetis Therapeutics AB (publ)'s Working Capital to Net Assets ratio has evolved across 17 annual periods from 2008 to 2024. As of June 2025, the ratio stands at 5.5%, reflecting working capital of Skr19.70 Million against net assets of Skr355.10 Million SEK. Check EGTX intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Egetis Therapeutics AB (publ) (2008–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Egetis Therapeutics AB (publ) from 2008 to 2024, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Egetis Therapeutics AB (publ) stock valuation.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 35.7% | Skr175.90 Million | Skr492.90 Million | Skr380.10 Million | Skr204.20 Million | ▼ -8.7 pp |
| 2023 | 44.4% | Skr242.00 Million | Skr545.60 Million | Skr345.90 Million | Skr103.90 Million | ▲ +25.0 pp |
| 2022 | 19.4% | Skr98.00 Million | Skr506.20 Million | Skr147.40 Million | Skr49.40 Million | ▼ -2.2 pp |
| 2021 | 21.6% | Skr113.73 Million | Skr527.04 Million | Skr152.90 Million | Skr39.17 Million | ▼ -14.9 pp |
| 2020 | 36.5% | Skr229.73 Million | Skr629.63 Million | Skr299.87 Million | Skr70.14 Million | ▼ -63.5 pp |
| 2019 | 100.0% | Skr244.87 Million | Skr244.88 Million | Skr269.95 Million | Skr25.08 Million | ▼ 0.0 pp |
| 2018 | 100.0% | Skr219.36 Million | Skr219.36 Million | Skr242.04 Million | Skr22.68 Million | ▲ +0.0 pp |
| 2017 | 100.0% | Skr303.71 Million | Skr303.71 Million | Skr315.37 Million | Skr11.66 Million | ▲ +0.0 pp |
| 2016 | 100.0% | Skr389.56 Million | Skr389.56 Million | Skr396.44 Million | Skr6.87 Million | ▼ 0.0 pp |
| 2015 | 100.0% | Skr48.03 Million | Skr48.03 Million | Skr52.36 Million | Skr4.33 Million | ▲ +0.1 pp |
| 2014 | 99.9% | Skr90.61 Million | Skr90.66 Million | Skr103.42 Million | Skr12.81 Million | ▲ +0.1 pp |
| 2013 | 99.9% | Skr46.90 Million | Skr46.95 Million | Skr50.96 Million | Skr4.06 Million | ▼ 0.0 pp |
| 2012 | 99.9% | Skr53.88 Million | Skr53.94 Million | Skr60.40 Million | Skr6.52 Million | ▼ -0.1 pp |
| 2011 | 100.0% | Skr87.52 Million | Skr87.53 Million | Skr91.41 Million | Skr3.89 Million | ▲ +110.1 pp |
| 2010 | -10.1% | Skr-705.58K | Skr6.99 Million | Skr796.90K | Skr1.50 Million | ▼ -13.4 pp |
| 2009 | 3.3% | Skr187.92K | Skr5.64 Million | Skr461.90K | Skr273.98K | ▼ -6.6 pp |
| 2008 | 9.9% | Skr500.00K | Skr5.05 Million | Skr823.56K | Skr323.55K | — |